2 article(s) from Cosford, Nicholas D P
In-flask (batch) preparation of imidazo[1,2-a]pyridin-2-yl-1,2,4-oxadiazoles (S1P1 agonists) .
Jump to Scheme 1
Gram-scale synthesis of mGlu5 NAM by continuous flow in combination with microfluidic extraction.
Jump to Scheme 2
Gram-scale synthesis of imidazo[1,2-a]pyridin-2-yl-1,2,4-oxadiazole S1P1 agonist scaffold by contin...
Jump to Scheme 3
Beilstein J. Org. Chem. 2017, 13, 239–246, doi:10.3762/bjoc.13.26
FDA-approved riluzole (1) and other ALS drugs currently in phase III clinical trials (2–6).
Jump to Figure 1
Riluzole (left) and prodrugs developed by McDonnell et al. .
Jump to Figure 2
Neurotransmitters N-acetyl-aspartyl glutamate (NAAG, top) and D-serine (bottom).
Jump to Figure 3
Thiopyridazines developed to increase EAAT2 protein levels.
Jump to Figure 4
Compounds shown to reduce SOD1 expression.
Jump to Figure 5
Families of compounds (named in italics) capable of reducing SOD1-induced cellular toxicity and mut...
Jump to Figure 6
Compounds identified by Nowak and co-workers  in silico that selectively bind SOD1 over human plasm...
Jump to Figure 7
4-Aminoquinolines developed by Cassel and co-workers  for disruption of oligonucleotide/TDP-43 bind...
Jump to Figure 8
Cu(II)(atsm), an example of a Cu(II)(btsc) copper complex.
Jump to Figure 9
Pharmacological inducers of autophagy.
Jump to Figure 10
Compounds used to evaluate the effects of trophic factors on ALS disease progression.
Jump to Figure 11
Compounds identified as neuroprotective.
Jump to Figure 12
Compounds developed to reduce oxidative stress and inflammation.
Jump to Figure 13
Probes used to elucidate the roles of distinct gene-expression profiles in ALS patients.
Jump to Figure 14
Targets of potential therapeutics: This diagram illustrates the physiological targets of each compo...
Jump to Figure 15
Beilstein J. Org. Chem. 2013, 9, 717–732, doi:10.3762/bjoc.9.82
Subscribe to our Latest Articles RSS Feed.
Register and get informed about new articles.
Follow the Beilstein-Institut